#USA #Inc. #Boston Scientific #Alameda #Penumbra #thrombectomy

Penumbra, Inc. Reports Strong Financial Results for Q2 2026

Penumbra, Inc. (NYSE: PEN), recognized as a leading innovator in thrombectomy, has announced its financial results for the second quarter ending June 30, 2026. This report displays significant revenue growth and a positive trajectory amid upcoming corporate developments.

Financial Highlights

In the second quarter of 2026, Penumbra achieved a revenue of $390 million. This marks an impressive 14.9% increase compared to the same quarter in the previous year, indicating a robust demand for its products and services.

Revenue Breakdown

The company saw growth across different categories, particularly in:

• - Thrombectomy Revenue: $259 million, up 12.5% from Q2 2025.
• - Embolization and Access Revenue: $131.1 million, reflecting a 20.0% increase year-over-year.

These numbers showcase the company’s expanding market share and solidify its position in the global medical device sector.

Profit Margins

Gross profit margins increased to 67.9%, up from 66% in the previous year’s second quarter. This enhanced profitability underscores the efficiency of Penumbra’s operational measures and its ability to manage expenses effectively.

Operating Expenses

Total operating expenses for the quarter were logged at $223.9 million, comprising $25.4 million for research and development (R&D) and $198.5 million for selling, general, and administrative (SGA) expenses. Notably, $6.9 million of these expenses relate to the forthcoming acquisition of Penumbra by Boston Scientific Corporation, highlighting strategic investments in growth and innovation.

Earnings Overview

For Q2 2026, Penumbra reported an operating income of $41 million and a net income of $34.8 million. The earnings per share for the quarter stood at $0.88 on a diluted basis. Compared to the previous year’s results, these figures reflect a solid operational performance despite the backdrop of an impending corporate transition.

Future Outlook and Strategic Developments

It’s important to note that Penumbra will not be issuing full-year financial guidance for 2026, due to the pending acquisition by Boston Scientific, which is expected to influence its financial and operational dynamics going forward.

About Penumbra, Inc.

Penumbra, Inc. has established itself as a pioneer in developing cutting-edge technologies aimed at treating severe medical conditions like ischemic stroke and venous thromboembolism. Its innovative product lineup, including the computer-assisted vacuum thrombectomy (CAVT) system, focuses on effectively eliminating blood clots to enhance patient care. The company proudly serves healthcare professionals in over 100 countries, proving its commitment to improving patient outcomes.

For those interested in following Penumbra’s journey, further information can be found at Penumbra's website and through its social media channels.

Conclusion

Overall, Penumbra’s Q2 2026 financial results demonstrate consistent growth and stability. With its strong performance metrics and an eye toward the future, Penumbra stands out as a key player in the medical device industry amid the unfolding changes associated with its acquisition by Boston Scientific. This combination of innovation and growth positions the company well in a competitive landscape, and stakeholders will be closely monitoring its developments in the coming months.